Literature DB >> 30842257

Treating Hypertension in Children With n-of-1 Trials.

Joyce P Samuel1, Jon E Tyson2, Charles Green2, Cynthia S Bell2, Claudia Pedroza2, Don Molony3, Joshua Samuels2,3.   

Abstract

OBJECTIVES: Clinicians prescribe antihypertensive medication to children with primary hypertension, but without data to define a particular choice as first-line therapy. A one-size-fits-all approach may not be appropriate for these patients. Our aim was to develop a personalized approach to hypertension treatment, using repeated ambulatory blood pressure monitoring (ABPM) in n-of-1 trials (single-patient randomized crossover trials).
METHODS: Children undergoing hypertension management at a single pediatric referral center were offered participation in an n-of-1 trial with repeated ABPM to compare 3 commonly used medications. The medication producing the greatest blood pressure reduction, and without unacceptable side effects, was selected as the preferred therapy for the individual.
RESULTS: Forty-two children agreed to participate; 7 were normotensive without medication; and 3 failed to complete one treatment cycle. Of the remaining 32 patients, lisinopril was preferred for 16, amlodipine for 8, hydrochlorothiazide for 4, and 4 had uncontrolled blood pressure on maximum doses of monotherapy. In conservative Bayesian analyses, the proportion of patients who preferred lisinopril was 49% (95% credible interval [CrI]: 32% to 69%), 24% (95% CrI: 12% to 41%) preferred amlodipine, and 12% (95% CrI: 4% to 26%) preferred hydrochlorothiazide. The preferred therapy for the majority (67%) of African American participants was lisinopril. Unacceptable side effects were reported in 24% of assessments for hydrochlorothiazide, 16% for lisinopril, and 13% for amlodipine.
CONCLUSIONS: No single medication was preferred for more than half of hypertensive children. n of-1 trials with repeated ABPM may promote better informed and individualized decisions in pediatric hypertension management.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30842257      PMCID: PMC6564074          DOI: 10.1542/peds.2018-1818

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  31 in total

1.  PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial.

Authors:  Joy M Schmitz; Charles E Green; Khader M Hasan; Jessica Vincent; Robert Suchting; Michael F Weaver; F Gerard Moeller; Ponnada A Narayana; Kathryn A Cunningham; Kelly T Dineley; Scott D Lane
Journal:  Addiction       Date:  2017-07-03       Impact factor: 6.526

2.  A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension.

Authors:  Ronald J Hogg; Angela Delucchi; Graciela Sakihara; Thomas G Wells; Frank Tenney; Donald L Batisky; Jeffrey L Blumer; Beth A Vogt; Man-Wai Lo; Elizabeth Hand; Deborah Panebianco; Ronda Rippley; Wayne Shaw; Shahnaz Shahinfar
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

3.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Authors:  Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork
Journal:  Per Med       Date:  2011-03       Impact factor: 2.512

4.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

5.  An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.

Authors:  C Jane Nikles; Geoffrey K Mitchell; Chris B Del Mar; Alexandra Clavarino; Norma McNairn
Journal:  Pediatrics       Date:  2006-06       Impact factor: 7.124

6.  Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association.

Authors:  Joseph T Flynn; Stephen R Daniels; Laura L Hayman; David M Maahs; Brian W McCrindle; Mark Mitsnefes; Justin P Zachariah; Elaine M Urbina
Journal:  Hypertension       Date:  2014-03-03       Impact factor: 10.190

7.  Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  R A Preston; B J Materson; D J Reda; D W Williams; R J Hamburger; W C Cushman; R J Anderson
Journal:  JAMA       Date:  1998-10-07       Impact factor: 56.272

8.  Randomized n-of-1 Trials: Quality Improvement, Research, or Both?

Authors:  Joyce P Samuel; Alyssa Burgart; Susan H Wootton; David Magnus; John D Lantos; Jon E Tyson
Journal:  Pediatrics       Date:  2016-07-06       Impact factor: 7.124

9.  CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.

Authors:  Sunita Vohra; Larissa Shamseer; Margaret Sampson; Cecilia Bukutu; Christopher H Schmid; Robyn Tate; Jane Nikles; Deborah R Zucker; Richard Kravitz; Gordon Guyatt; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2015-05-14

Review 10.  When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment.

Authors:  Denes Szucs; John P A Ioannidis
Journal:  Front Hum Neurosci       Date:  2017-08-03       Impact factor: 3.169

View more
  6 in total

Review 1.  High Blood Pressure in Children and Adolescents: Current Perspectives and Strategies to Improve Future Kidney and Cardiovascular Health.

Authors:  Cal H Robinson; Rahul Chanchlani
Journal:  Kidney Int Rep       Date:  2022-03-01

Review 2.  Blood Pressure in Childhood and Adolescence.

Authors:  Shakia T Hardy; Elaine M Urbina
Journal:  Am J Hypertens       Date:  2021-04-02       Impact factor: 3.080

3.  Comparison of Aggregated N-of-1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies.

Authors:  J Walker Blackston; Andrew G Chapple; James M McGree; Suzanne McDonald; Jane Nikles
Journal:  Healthcare (Basel)       Date:  2019-11-06

4.  Evaluating the Comparative Effectiveness of Two Diets in Pediatric Inflammatory Bowel Disease: A Study Protocol for a Series of N-of-1 Trials.

Authors:  Heather C Kaplan; Lisa Opipari-Arrigan; Christopher H Schmid; Christine L Schuler; Shehzad Saeed; Kimberly L Braly; Jennifer C Burgis; Kaylie Nguyen; Sheri Pilley; Julie Stone; Gisele Woodward; David L Suskind
Journal:  Healthcare (Basel)       Date:  2019-11-01

5.  Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.

Authors:  Catherine G Derington; Jordan B King; Thomas Delate; Sheila R Botts; Miranda Kroehl; David P Kao; Katy E Trinkley
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

6.  Personal preferences for Personalised Trials among patients with chronic diseases: an empirical Bayesian analysis of a conjoint survey.

Authors:  Ying Kuen Cheung; Dallas Wood; Kangkang Zhang; Ty A Ridenour; Lilly Derby; Tara St Onge; Naihua Duan; Joan Duer-Hefele; Karina W Davidson; Ian Kronish; Nathalie Moise
Journal:  BMJ Open       Date:  2020-06-07       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.